Marshall Wace North America’s Aimmune Therapeutics AIMT Stock Holding History

Marshall Wace North America’s Portfolio AIMT Stock Details AIMT Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2020 Q4	–	Sell	-20,702	Closed	-$713K	–	1723
2020 Q3	$713K	Sell	20,702 -59,812	-74%	-$1.27M	﹤0.01%	887
2020 Q2	$1.34M	Buy	+80,514	New	+$1.37M	0.01%	681
2019 Q4	–	Sell	-272,536	Closed	-$5.71M	–	1742
2019 Q3	$5.71M	Buy	+272,536	New	+$5.56M	0.03%	343
2019 Q2	–	Sell	-1,418	Closed	-$32K	–	1824
2019 Q1	$32K	Buy	+1,418	New	+$33.4K	﹤0.01%	1330
2018 Q1	–	Sell	-296,651	Closed	-$11.2M	–	1814
2017 Q4	$11.2M	Buy	+296,651	New	+$9.57M	0.06%	349

Marshall Wace North America's AIMT Position: Q4 2020 in Review

Marshall Wace North America sold out of Aimmune Therapeutics (AIMT) in Q4 2020, closing a stake of 20,702 shares — an estimated $713K sold.

Marshall Wace North America first reported a position in AIMT in Q4 2017 and held it in 5 quarters. The position peaked at $11.2M in Q4 2017. 0 funds tracked by Wall St. Rank hold AIMT as of Q4 2020.

Marshall Wace North America reported no remaining Aimmune Therapeutics position as of Q4 2020 after selling out during the quarter.
Marshall Wace North America sold 20,702 Aimmune Therapeutics shares in Q4 2020, an estimated $713K.
Marshall Wace North America first reported a position in Aimmune Therapeutics in Q4 2017 and held it in 5 quarters.
Marshall Wace North America's Aimmune Therapeutics position peaked at $11.2M in Q4 2017.
0 funds tracked by Wall St. Rank held Aimmune Therapeutics as of Q4 2020.

Based on Marshall Wace North America's 13F filing for Q4 2020, filed 16 Feb 2021.